Related Experiment Videos
Cardioprotective effect of desferrioxamine
A Bel1, E Martinod, P Menasché
1Service de Chirurgie Cardio-Vasculaire, Hôpital Lariboisière, Paris, France.
Acta Haematologica
|January 1, 1996
Summary
Desferrioxamine, an iron chelator, reduces harmful free radical generation during cardiac surgery involving cardiopulmonary bypass and ischemia-reperfusion. Despite demonstrated biological effects, it has not improved patient outcomes after surgery.
Area of Science:
- Cardiovascular Surgery
- Free Radical Biology
- Pharmacology
Background:
- Cardiac surgery often involves cardiopulmonary bypass, leading to ischemia-reperfusion.
- This process generates highly cytotoxic free radical species.
- Iron plays a key role in this radical generation.
Purpose of the Study:
- To evaluate the clinical efficacy of desferrioxamine in cardiac surgery.
- To determine if reducing free radical generation translates to improved patient outcomes.
Main Methods:
- Review of animal and clinical studies on desferrioxamine use.
- Analysis of desferrioxamine's effect on free radical species during bypass and ischemia-reperfusion.
Main Results:
- Desferrioxamine, an iron chelator, effectively reduces free radical generation in these settings.
- Studies consistently show a biological role for desferrioxamine in mitigating radical species.
Conclusions:
- The biological benefits of desferrioxamine in reducing free radicals are well-established.
- However, this has not yet led to demonstrable improvements in postoperative patient outcomes.